<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015547</url>
  </required_header>
  <id_info>
    <org_study_id>211864, 318/E0/2002</org_study_id>
    <secondary_id>211864</secondary_id>
    <nct_id>NCT01015547</nct_id>
  </id_info>
  <brief_title>Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis</brief_title>
  <acronym>ACUTE-JIA</acronym>
  <official_title>Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Paediatric Research, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PÃ¤ivikki and Sakari Sohlberg Foundation, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rheumatism Foundation Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scandinavian Rheumatology Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paijat-Hame Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare in very early polyarticular juvenile idiopathic
      arthritis (JIA) the efficacy, safety, and cost-benefit-ratio of three treatment strategies:
      biologic combination, combination of conventional disease-modifying drugs (DMARDs), and
      methotrexate alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DMARD-naive polyarticular JIA patients with an early disease (onset less than 6 months) are
      randomized into one of three treatment strategies: (1) biological combination, i.e., anti-TNF
      therapy with infliximab plus methotrexate; (2) Combination of DMARDs with methotrexate,
      sulfasalazine, plus hydroxychloroquine; and (3) Methotrexate alone.

      The efficacy is evaluated by American College of Rheumatology Pediatric (ACR Pedi) criteria
      based on 6 core set variables (CSVs): 1. no of active joints; 2. no. of joints with pain or
      tenderness and limitation of motion; 3. ESR (mm/hr); 4. the Childhood Health Assessment
      Questionnaire (CHAQ); 5. Physician's Visual Analogue Scale (VAS); 6. Patient/Parent VAS. To
      fulfill ACR Pedi 75 criteria, 3/6 CSVs have to improve 75% and not more than 1/6 CSV worsen
      more than 30%. All direct and indirect costs are documented.

      The first phase of the study is open-label clinical trial lasting for 54 weeks. In the second
      phase of the study the patients are followed up to 5 years, and the long-term outcome of
      early aggressive therapy is analyzed. Serum, urine, and saliva samples are collected at 3 and
      5 years for translational research.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR Pedi 75 response</measure>
    <time_frame>54 weeks from baseline (0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinically inactive disease</measure>
    <time_frame>at 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time spent in inactive disease</measure>
    <time_frame>0 to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time spent in ACR Pedi 75</measure>
    <time_frame>0 to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other ACR Pedi responses (30, 50, 70, 90, 100)</measure>
    <time_frame>0 to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug survival</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of side-effects and adverse events</measure>
    <time_frame>0 to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-benefit ratio in each treatment arm</measure>
    <time_frame>0 to 54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Infliximab plus Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of DMARDs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab plus methotrexate</intervention_name>
    <description>IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.</description>
    <arm_group_label>Infliximab plus Methotrexate</arm_group_label>
    <other_name>IFX: Remicade, MTX: Trexan or Methotrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of DMARDs</intervention_name>
    <description>IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.</description>
    <arm_group_label>Combination of DMARDs</arm_group_label>
    <other_name>MTX: Trexan or Methotrexate, SSZ: Salazopyrin, HCQ: Oxiklorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate alone</intervention_name>
    <description>Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.</description>
    <arm_group_label>Methotrexate alone</arm_group_label>
    <other_name>MTX: Trexan or Methotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  juvenile idiopathic arthritis

          -  arthritis lasting for at least 6 weeks but not more than 6 months

          -  polyarticular disease with at least 5 active joints with at least 3 joints with pain
             or tenderness and limitation of motion

          -  no previous treatment with DMARDs

        Exclusion Criteria:

          -  systemic JIA

          -  any abnormality in the hematopoietic or lymphatic system

          -  any major concurrent medical condition

          -  inadequate psychosocial situation

          -  pregnancy

          -  a non-abstinent female with reproductive capacity without regular contraceptive use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pekka Lahdenne, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital for Children and Adolescents in Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatism Foundation Hospital</name>
      <address>
        <city>Heinola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Children and Adolescents</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Central Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Lahdenne P, VÃ¤hÃ¤salo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003 Mar;62(3):245-7.</citation>
    <PMID>12594111</PMID>
  </reference>
  <results_reference>
    <citation>TynjÃ¤lÃ¤ P, VÃ¤hÃ¤salo P, Tarkiainen M, KrÃ¶ger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011 Sep;70(9):1605-12. doi: 10.1136/ard.2010.143347. Epub 2011 May 28.</citation>
    <PMID>21623000</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Pirjo Tynjala</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>juvenile idiopathic arthritis</keyword>
  <keyword>polyarthritis</keyword>
  <keyword>combination therapy</keyword>
  <keyword>biologic agents</keyword>
  <keyword>TNF antagonists</keyword>
  <keyword>infliximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

